Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HUBS

Go back to Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
(NASDAQ: HELP) Delayed: 12.22 +0.45 (3.82%)
Previous Close $11.77    52 Week High $ 
Open $11.81    52 Week Low $ 
Day High $12.26    P/E N/A 
Day Low $11.44    EPS $ 
Volume 1,026,783       

(NASDAQ: HELP) Delayed: 12.22 +0.45 (3.82%)
Previous Close $11.77    52 Week High $ 
Open $11.81    52 Week Low $ 
Day High $12.26    P/E N/A 
Day Low $11.44    EPS $ 
Volume 1,026,783